TMCnet News
Technologies for Cancer Research Report 2017: Technology Innovations & Pharmaceuticals Pipeline and Industry Interactions - Research and MarketsResearch and Markets has announced the addition of the "Technologies for Cancer Research" report to their offering. Cancer therapeutics are rapidly evolving with better targets and biologics. The greatest therapeutic current need is present across the indication of cancer. With each individual having a different and more unpredictable form of the disease, the need for personalized medicine is far greater. Hence, novel drug discovery technologies and drug delivery mechanisms are continuously being researched. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Key Topics Covered: 1. Cancer Research Technology Innovations - Throwing Light on Deprioritized/Under-resourced Anti-Cancer Agents - Programming Cancer Cell Death through the Neuro-Signaling Approach - Introducing Combined Theranostic Approaches in Cancer - Targeting Chronic Lymphocytic Leukemia through Restoration of Cancer Cell Apoptosis - Novel Cancer Therapy for the Treatment of Soft Tissue Sarcoma - Priority Review from the FDA for a Drug Targeted toward Liver Cancer - Monotherapy for Newly Diagnosed Multiple Myeloma Patients 2. Cancer Pharmaceuticals Pipeline and Industry Interactions (News - Alert) - Pipeline Analysis - Clinical Trials - Industry Interactions For more information about this report visit http://www.researchandmarkets.com/research/t4rjf3/technologies_for
View source version on businesswire.com: http://www.businesswire.com/news/home/20170329005523/en/ |
